Non-invasive assessment of liver fibrosis and prognosis: an update on serum and elastography markers
Uchenna Agbim & Sumeet K Asrani
Received 10 Aug 2018, Accepted 04 Feb 2019, Accepted author version posted online: 06 Feb 2019
Introduction: Non-invasive assessment of fibrosis is increasingly utilized in clinical practice to diagnose hepatic fibrosis. Non-invasive assessment of liver fibrosis relies on biologic and/or physical properties to assess tissue fibrosis. Serum markers estimate fibrosis by incorporating markers reflecting hepatic function (indirect markers) and/or markers measuring extracellular matrix degradation/fibrogenesis (direct markers). Radiology based techniques relay the mechanical properties and stiffness of a tissue, with increased stiffness associated with more advanced fibrosis.
Areas covered: In this comprehensive review, the recent literature discussing serum markers and elastography-based techniques will be covered. These modalities are also explored in the setting of various liver diseases.
Expert opinion: The etiology of liver disease and clinical context should be taken into consideration when non-invasive markers are incorporated in clinical practice. Non-invasive assessment of fibrosis has been most extensively utilized in hepatitis C, followed by hepatitis B and nonalcoholic fatty liver disease, but its role remains less developed in other etiologies of liver disease such as alcohol associated liver disease and autoimmune liver disease. The role of non-invasive markers in predicting progression or regression of fibrosis, development of liver related events and survival needs to be further explored.
Keywords: elastography, hepatitis C, hepatitis B, liver fibrosis, liver stiffness, magnetic resonance elastography, nonalcoholic fatty liver disease, shear wave elastography, vibration-controlled transient elastography作者: StephenW 时间: 2019-2-7 22:52
肝纤维化和预后的非侵入性评估:血清和弹性成像标志物的更新
Uchenna Agbim和Sumeet K Asrani
收稿日期2018年8月10日,接受于2019年2月4日,接受作者发布于2019年2月6日